1. Alam S, Zawadzki RJ, Choi S, et al. Clinical application of rapid serial fourier-domain optical coherence tomography for macular imaging. Ophthalmology. 2006; 113:1425–31.
Article
2. Nassif N, Cense B, Park BH, et al. In vivo human retinal imaging by ultrahigh-speed spectral domain optical coherence tomography. Opt Lett. 2004; 29:480–2.
Article
3. Lee SH, Chung H, Kim HC. Subfoveal choroidal thickness in fellow eyes of patients with central serous chorioretinopathy. J Korean Ophthalmol Soc. 2012; 53:982–7.
Article
4. Kim JH, Kang SW, Park DY, et al. Asymmetric elongation of foveal tissue after macular hole surgery and its impact on metamorphopsia. Ophthalmology. 2012; 119:2133–40.
Article
5. Brown DM, Chen E, Mariani A, Major JC Jr. Super-dose anti-VEGF (SAVE) trial: 2.0 mg intravitreal ranibizumab for recalcitrant neovascular macular degeneration-primary end point. Ophthalmology. 2013; 120:349–54.
Article
6. Cohen SY, Dubois L, Nghiem-Buffet S, et al. Spectral domain optical coherence tomography analysis of macular changes in tilted disk syndrome. Retina. 2013; 33:1338–45.
Article
7. Yeung L, Lima VC, Garcia P, et al. Correlation between spectral domain optical coherence tomography findings and fluorescein angiography patterns in diabetic macular edema. Ophthalmology. 2009; 116:1158–67.
Article
8. Bolz M, Kriechbaum K, Simader C, et al. In vivo retinal morphology after grid laser treatment in diabetic macular edema. Ophthalmology. 2010; 117:538–44.
Article
9. Haritoglou C, Kook D, Neubauer A, et al. Intravitreal bevacizumab (Avastin) therapy for persistent diffuse diabetic macular edema. Retina. 2006; 26:999–1005.
Article
10. Paccola L, Costa RA, Folgosa MS, et al. Intravitreal triamcinolone versus bevacizumab for treatment of refractory diabetic macular oedema (IBEME study). Br J Ophthalmol. 2008; 92:76–80.
Article
11. Yanyali A, Aytug B, Horozoglu F, Nohutcu AF. Bevacizumab (Avastin) for diabetic macular edema in previously vitrectomized eyes. Am J Ophthalmol. 2007; 144:124–6.
Article
12. Jeong JH, Kim ES, Lee JK, et al. The effects of intravitreal bevacizumab injection according to the type of diabetic macular edema. J Korean Ophthalmol Soc. 2010; 51:700–6.
Article
13. Lee SJ, Kim ET, Moon YS. Intravitreal bevacizumab alone versus combined with macular photocoagulation in diabetic macular edema. Korean J Ophthalmol. 2011; 25:299–304.
Article
14. Maheshwary AS, Oster SF, Yuson RM, et al. The association between percent disruption of the photoreceptor inner segment-outer segment junction and visual acuity in diabetic macular edema. Am J Ophthalmol. 2010; 150:63–7.e1.
Article
15. Otani T, Yamaguchi Y, Kishi S. Correlation between visual acuity and foveal microstructural changes in diabetic macular edema. Retina. 2010; 30:774–80.
Article
16. Shin HJ, Lee SH, Chung H, Kim HC. Association between photoreceptor integrity and visual outcome in diabetic macular edema. Graefes Arch Clin Exp Ophthalmol. 2012; 250:61–70.
Article
17. Sakamoto A, Nishijima K, Kita M, et al. Association between foveal photoreceptor status and visual acuity after resolution of diabetic macular edema by pars plana vitrectomy. Graefes Arch Clin Exp Ophthalmol. 2009; 247:1325–30.
Article
18. Lim JH, Kim IH, Bae GH, et al. Analysis of optical coherence tomographic patterns and clinical courses in diabetic macular edema after treatment. J Korean Ophthalmol Soc. 2014; 55:222–9.
Article
19. Kim JH, Kang SW, Ha HS, et al. Overestimation of subfoveal choroidal thickness by measurement based on horizontally compressed optical coherence tomography images. Graefes Arch Clin Exp Ophthalmol. 2013; 251:1091–6.
Article